增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析

doi:10.3969/j.issn.1672-5069.2022.04.037

Abstract

Wei Bowen, Ren Zheng, Zhang Liang, et al. Enhanced CT scanning in evaluating residual tumor in patients with primary liver cancer after TACE theapy[J]. Journal of Practical Hepatology, 2022, 25(4): 603-604.

References

[1] Elsholtz F, Ro S R, Shnayien S,et al. Inter- and intrareader agreement of NI-RADS in the interpretation of surveillance contrast-enhanced CT after treatment of oral cavity and oropharyngeal squamous cell carcinoma. Am J Neuroradiol, 2020,41(5):26-27.
[2] Li M, Li MX, Li MD, et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST. Eur Radiol, 2020,25(8):25-27.
[3] Xu H, Wei W, Mu Y, et al. Efficacy and safety of Chinese patent medicine (Jinlong capsule) in the treatment of advanced hepatocellular carcinoma: a meta-analysis. Biosci Rep, 2020,40(1):16-18.
[4] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011 年版).临床肿瘤学杂志 2011,16(10):929-946.
[5] Zeng Y Y, Guo W H, Zhang Z,et al. A real-world study of camrelizumab in the treatment of hepatocellular carcinoma. J Clin Oncol, 2021, 39(15):16121-16121.
[6] Moten A, Lau K N . Racial disparity in the treatment of hepatocellular carcinoma: Have times changed. J Am Coll Surg,2020, 231(4):167-168.
[7] 徐学清,李炳超,冯铠莉.增强CT纹理技术对TACE治疗的原发性肝癌患者术后肿瘤短期进展的预测价值.实用肝脏病杂志,2020,23(3):4-6.
[8] Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol,2020,73(2):342-348.
[9] Long G, Fang T, Su W, et al. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scan J Gastroenterol,2020,55(12):1441-1446.
[10] 吴水天. 增强CT扫描在评估原发性肝癌TACE术后疗效中的应用. 中国CT和MRI杂志, 2022, 20(3):3-5.

[1]	Liu Lin, Hu Yun, Xu Lan. Lifestyle management of individuals with glucose and lipid metabolism disorders- related diseases [J]. Journal of Practical Hepatology, 2022, 25(4): 464-467.
[2]	Liu Yuying, Zhang Jiaozhen, Zhou Haijuan, et al. Response to tenofovir antiviral therapy different in patients with chronic hepatitis B and different HBV genotype infection? [J]. Journal of Practical Hepatology, 2022, 25(4): 492-495.
[3]	Xu Huan, Wang Guangli, Dong Dandan, et al. Efficacy of standardized pegylated interferon α-2a and ribavirin combination in treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 500-503.
[4]	Li Yawen, Zhou Jun. Clinical efficacy of Huatan Qushi Shugan decoction and simvastatin combination in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(4): 526-529.
[5]	Ji Xuechun, Jin Shizhu, Nipal Narayan, et al. Endoscopic management of superior esophageal variceal bleeding: a 10-year single center retrospective experience [J]. Journal of Practical Hepatology, 2022, 25(4): 530-533.
[6]	Wang Baofeng, Ma Yangao, Li Yi, et al. Diagnostic efficacy of GD-EOB-DTPA enhanced MRI in differentiation of primary liver cancer from nodular regenerative hyperplasia of liver in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(4): 554-557.
[7]	Liu Hao, Zhou Feifei, Sun Haokai, et al. CBCT-based 3D reconstruction technique in the identification of blood supplying arteries during TACE operation for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(4): 563-566.
[8]	Wang Yuanping, Zheng Lulu, Zhang Guangliang. A pilot study of MR and 4DCT images in the delineation of target area in patients with primary liver cancer undergoing first radiotherapy [J]. Journal of Practical Hepatology, 2022, 25(4): 567-570.
[9]	Zhang Jing, Lin Ting, Sun Xiang. Percutaneous cather drainage under ultrasound guidance with lauromacrogol replacement for sclerotherapy in patients with huge hepatic cysts [J]. Journal of Practical Hepatology, 2022, 25(4): 571-574.
[10]	Wang Jing, Zhang Jie, Zhao Jing. Differentiation of hepatic hemangioma from hepatocellular carcinoma by contrast ultrasonography and virtual touch tissue quantification: An analysis of 93 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 575-578.
[11]	Lin Yikun, Xie Lang, Fu Jianming, et al. Clinical efficacy of partial hepatectomy and choledochojejunostomy combination in the treatment of patients with hepatolithiasis and risk factors for postoperative recurrence [J]. Journal of Practical Hepatology, 2022, 25(4): 591-594.
[12]	Huang Peng, Meng Fanbin, Zhang Xiao, et al. Efficacy of percutaneous transhepatic puncture choledochoscopic lithotomy under CT 3D guidance in the treatment of patients with complex hepatolithiasis [J]. Journal of Practical Hepatology, 2022, 25(4): 595-598.
[13]	Zou Ji, Chen Xiaobo, Dong Renhua, et al. Long-term survival of patients with stageT1b gallbladder cancer after cholecystectomy and wedge resection of liver tissues and regional lymph node dissection combination therapy [J]. Journal of Practical Hepatology, 2022, 25(4): 599-602.
[14]	Huang Junrong, Wu Changru, Wu Jianlin. Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 327-330.
[15]	Zou Donghua, Mi Jianwei, Li Yuling, et al. Rescued therapy of patients with chronic hepatitis B and rtA181V/T mutation by adefovir dipivoxiland entecavir or tenofovir combination [J]. Journal of Practical Hepatology, 2022, 25(3): 331-334.

Enhanced CT scanning in evaluating residual tumor in patients with primary liver cancer after TACE theapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments